Evolving Treatment Strategies for Noninfectious Uveitis

Advances in corticosteroid delivery, systemic immunomodulation, and pipeline therapies are expanding options for individualized management.

1

Recent advances in treatment for noninfectious uveitis include corticosteroid delivery, systemic immunomodulation, and new pipeline therapies.
2

Corticosteroids remain the primary treatment for acute ocular inflammation, with local therapies minimizing systemic side effects.
3

The fluocinolone acetonide 0.19-mg intravitreal implant provides sustained corticosteroid delivery for up to 36 months, improving recurrence rates.
4

Suprachoroidal triamcinolone acetonide was approved to treat uveitic macular edema, offering targeted therapy with a favorable safety profile.
5

Biologic agents like adalimumab and infliximab are used for NIU when conventional therapies fail, allowing selective inhibition of inflammatory pathways.

1